We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 841

In determining patent term extensions under 35 U.S.C. 156, the statutory term “active ingredient” means the product, not the active moiety of the product, that is present in the approved drug

  • Winston & Strawn LLP
  • -
  • USA
  • -
  • May 18 2010

The patentee owned a patent to a chemical compound MAL hydrochloride (“MAL”), which was patented and received FDA approval to treat precancerous cell growths on the skin

Employee charged with theft of company trade secrets

  • Epstein Becker Green
  • -
  • USA
  • -
  • February 9 2010

The importance of corporate security and vigilance with regard to trade secrets was demonstrated by recent events in Syracuse, New York

US company granted “orphan drug status” to find cure for rare blindness syndrome

  • RPC
  • -
  • USA
  • -
  • April 14 2010

Advanced Cell Technology, a US pharmaceutical company, has been granted beneficial "orphan drug" status under the Orphan Drug Act by the US Food and Drug Administration for an embryonic stem cell therapy which it is developing to treat Stargardt's Macular Dystrophy, a rare form of blindness

Sanofi-Aventis v. Laboratoire Riva; interlocutory motion on 55.2 proceeding; December 14, 2007 - Ramipril

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 17 2008

After cross-examinations had taken place, and approximately one week before the application record of Sanofi-Aventis was due, Riva brought a motion for leave to file further evidence

Patent settlement agreements come under Commission scrutiny

  • Nabarro LLP
  • -
  • European Union
  • -
  • January 28 2010

Hot on the heels of the pharmaceutical sector inquiry in 2009 and the formal proceedings opened against Lundbeck, the European Commission revealed that it sent requests to a number of large pharmaceutical companies for copies of recent patent settlement agreements

A district court has subject matter jurisdiction to conduct contempt proceedings in an ANDA litigation, but filing of a second ANDA does not violate an injunction where the injunction does not prohibit such a filing

  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • -
  • USA
  • -
  • December 31 2007

In Abbott Laboratories v. TorPharm, Inc., No. 07-1019 (Fed. Cir. Oct. 11, 2007), the Federal Circuit upheld the district court’s decision to hold a contempt proceeding on whether Nu-Pharm, Inc.’s (“Nu-Pharm”) filing of an ANDA violated an injunction against TorPharm, Inc., Apotex, Inc., and Apotex Corporation (collectively “Apotex”), but it reversed the district court’s finding of contempt because the injunction contained no “explicit notice” to Apotex that the filing of a new ANDA, by itself or a straw party, was forbidden

The FTC's latest remarks in opposition to reverse payment settlements: banning them would save consumers $35 billion

  • Sheppard Mullin Richter & Hampton LLP
  • -
  • USA
  • -
  • July 9 2009

The Federal Trade Commission's Chairman, Jon Leibowitz, continued the FTC's aggressive campaign against reverse payment settlements (also called "pay-for-delay" or "exclusion" settlements) by delivering a speech at the Center for American Progress entitled "'Pay-for Delay' Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers' Wallets, and Help Pay for Health Care Reform (The $35 Billion Solution)" (June 23, 2009

The government official report on patent protection for biotechnological inventions

  • Bird & Bird
  • -
  • Sweden
  • -
  • May 7 2008

The Directive on the legal protection of biotechnological inventions (9844EC) was implemented in Swedish law in 2004

FDA issues guidance on antibiotic patent listing law

  • Hogan Lovells
  • -
  • USA
  • -
  • December 1 2008

As described in an earlier Pharmaceutical and Biotechnology Update, last October President Bush signed into law the Qualifying Individual Program Supplemental Funding Act of 2008 (the “QI Act”

Potential impact of extending the 30-month stay under the Hatch-Waxman Act

  • Alston & Bird LLP
  • -
  • USA
  • -
  • March 3 2009

On February 24, 2009, a divided panel of the U.S. Court of Appeals for the Federal Circuit issued a decision that could impact patent litigation under the Hatch-Waxman Actin particular, a court’s ability to alter the statutory 30-month stay of FDA approval of abbreviated new drug applications under 21 U.S.C. 355(j)(5)(B)(iii